Cargando…

Lipoxins as biomarkers of lupus and other inflammatory conditions

Inflammatory events persist in systemic lupus erythematosus (lupus) despite the use of anti-inflammatory (both steroidal and non-steroidal) and immunosuppressive drugs leading to delay in the healing/repair process and so tissue/organ damage continues. The continuation of inflammation in lupus could...

Descripción completa

Detalles Bibliográficos
Autor principal: Das, Undurti N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3114772/
https://www.ncbi.nlm.nih.gov/pubmed/21569625
http://dx.doi.org/10.1186/1476-511X-10-76
_version_ 1782206109854990336
author Das, Undurti N
author_facet Das, Undurti N
author_sort Das, Undurti N
collection PubMed
description Inflammatory events persist in systemic lupus erythematosus (lupus) despite the use of anti-inflammatory (both steroidal and non-steroidal) and immunosuppressive drugs leading to delay in the healing/repair process and so tissue/organ damage continues. The continuation of inflammation in lupus could be attributed to failure of the resolution process due to deficiency of potent endogenous pro-resolution-inducing molecules such as lipoxin A(4 )(LXA(4)). It is likely that progression and flares of lupus and lupus nephritis are due to decreased formation and release of LXA(4). Hence, administration of LXA(4 )and its analogues could be of benefit in lupus. Furthermore, plasma and urinary measurement of lipoxins may be used to predict prognosis and response to therapy. It is likely that lipoxins and other bioactive anti-inflammatory lipids such as resolvins, protectins, maresins and nitrolipids play a significant role in other auto-immune diseases such as rheumatoid arthritis, type 1 diabetes mellitus and multiple sclerosis and hence, could be of significant benefit in these diseases.
format Online
Article
Text
id pubmed-3114772
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-31147722011-06-15 Lipoxins as biomarkers of lupus and other inflammatory conditions Das, Undurti N Lipids Health Dis Hypothesis Inflammatory events persist in systemic lupus erythematosus (lupus) despite the use of anti-inflammatory (both steroidal and non-steroidal) and immunosuppressive drugs leading to delay in the healing/repair process and so tissue/organ damage continues. The continuation of inflammation in lupus could be attributed to failure of the resolution process due to deficiency of potent endogenous pro-resolution-inducing molecules such as lipoxin A(4 )(LXA(4)). It is likely that progression and flares of lupus and lupus nephritis are due to decreased formation and release of LXA(4). Hence, administration of LXA(4 )and its analogues could be of benefit in lupus. Furthermore, plasma and urinary measurement of lipoxins may be used to predict prognosis and response to therapy. It is likely that lipoxins and other bioactive anti-inflammatory lipids such as resolvins, protectins, maresins and nitrolipids play a significant role in other auto-immune diseases such as rheumatoid arthritis, type 1 diabetes mellitus and multiple sclerosis and hence, could be of significant benefit in these diseases. BioMed Central 2011-05-15 /pmc/articles/PMC3114772/ /pubmed/21569625 http://dx.doi.org/10.1186/1476-511X-10-76 Text en Copyright ©2011 Das; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Hypothesis
Das, Undurti N
Lipoxins as biomarkers of lupus and other inflammatory conditions
title Lipoxins as biomarkers of lupus and other inflammatory conditions
title_full Lipoxins as biomarkers of lupus and other inflammatory conditions
title_fullStr Lipoxins as biomarkers of lupus and other inflammatory conditions
title_full_unstemmed Lipoxins as biomarkers of lupus and other inflammatory conditions
title_short Lipoxins as biomarkers of lupus and other inflammatory conditions
title_sort lipoxins as biomarkers of lupus and other inflammatory conditions
topic Hypothesis
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3114772/
https://www.ncbi.nlm.nih.gov/pubmed/21569625
http://dx.doi.org/10.1186/1476-511X-10-76
work_keys_str_mv AT dasundurtin lipoxinsasbiomarkersoflupusandotherinflammatoryconditions